Compare Prologis Inc (PLD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Prologis Inc trades at $130.46 (market cap $126.92B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Prologis Inc is far larger — about 26× Travere Therapeutics Inc. Common Stock's market cap, and Prologis Inc pays a 3.2% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PLD | TVTX | |
|---|---|---|
Market Cap | $126.92B | $4.88B |
Volume | 4,456,134 | 1,668,577 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $67.52 |
52-Week Low | $121.17 | $26.79 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $161.66B | $5.01B |
Dividend Yield | 3.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $130.53, down 1.46% on the day, with strong fundamentals including 45.79% net income margin and consistent earnings beats. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages, trading near support at $130. Recent news highlights leasing growth and data center expansion opportunities, while institutional buying continues.
Outlook remains positive with 61.9% analyst buy ratings and $155.15 consensus target offering 19% upside. Key risks include elevated valuation multiples (P/E 29.74) and rising debt-to-asset ratio (37.2% in 2025). The company's logistics real estate portfolio benefits from e-commerce and data center demand trends.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
